Výsledky vyhledávání - "Patrick M. Travis"

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial

Autor: Frederick Lansigan, Jeff P. Sharman, Patrick M Travis, Ian W. Flinn, Michael S. Weiss, Kathryn S. Kolibaba, Jason C. Chandler, Stephen J. Schuster, Hari P. Miskin, Suman Kambhampati, Nilanjan Ghosh, Danielle M. Brander, Scott D. Lunin, John M. Burke, Mikhail Shtivelband, Anthony R. Mato, Alexander Zweibach, Peter Sportelli, Marshall T. Schreeder

Publikováno v: The Lancet Haematology. 8:e254-e266

Summary Background Patients with chronic lymphocytic leukaemia and high-risk features have poorer outcomes on ibrutinib than those without high-risk features. The aim of this study was to assess the benefit of adding ublituximab, an anti-CD20 monoclo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc1704debdbf4edf7ce0038f0c02e284
https://doi.org/10.1016/s2352-3026(20)30433-6

Zobrazit plný text záznamu

Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study

Autor: Kathryn S. Kolibaba, Jason C. Chandler, Michael S. Weiss, John M. Burke, Hari P. Miskin, Alexander Zweibach, Nilanjan Ghosh, Patrick M. Travis, Frederick Lansigan, Ian W. Flinn, Stephen J. Schuster, Suman Kambhampati, Marshall T. Schreeder, Mikhail Shtivelband, Danielle M. Brander, Anthony R. Mato, Scott D. Lunin, Peter Sportelli, Jeff P. Sharman

Publikováno v: Journal of Clinical Oncology. 38:8022-8022

8022 Background: The BTK inhibitor ibrutinib (IB) has advanced the treatment for patients (pts) with CLL, however, among pts with high-risk CLL, disease control with IB is less durable. Ublituximab (UTX) is a glycoengineered mAb with enhanced ADCC. T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fa3422e8a7012a15061b791515a19fda
https://doi.org/10.1200/jco.2020.38.15_suppl.8022

Zobrazit plný text záznamu

UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALLY HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF THE GENUINE PHASE 3 STUDY

Autor: Frederick Lansigan, Ian W. Flinn, Anthony R. Mato, Suman Kambhampati, Mikhail Shtivelband, Alexander Zweibach, Scott D. Lunin, Marshall T. Schreeder, Patrick M. Travis, Kathryn S. Kolibaba, Hari P. Miskin, Peter Sportelli, Nilanjan Ghosh, Michael S. Weiss, Jason C. Chandler, Danielle M. Brander, John M. Burke, Jeff Porter Sharman

Publikováno v: Hematological Oncology. 35:111-112

7504 Background: Patients (pts) with high-risk chronic lymphocytic leukemia (CLL) defined by interruptions in TP53 (either by mutation or deletion) or loss of chromosome 11q experience inferior outcomes with ibrutinib (IB) monotherapy (O’Brien ASH

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91013645bf769ce2f20007ae9cd1db98
https://doi.org/10.1002/hon.2437_100

Zobrazit plný text záznamu

Mode of chemotherapy does not affect complications with an implantable venous access device

Autor: JoAnn Weller, Sharon R. Vire, Danielle F. Brown, Martin Hauer-Jensen, Patrick M. Travis, Michael J. Muirhead

Publikováno v: Cancer. 80:966-972

BACKGROUND Few reports have been made regarding the long term safety of implantable venous access devices used for the delivery of chemotherapeutic agents. The authors' goals were to determine the frequency of complications in patients receiving chem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f7a29decf8f42370ff3da706cd780de8
https://doi.org/10.1002/(sici)1097-0142(19970901)80:5<966::aid-cncr20>3.0.co

Zobrazit plný text záznamu

Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol

Autor: Charles Scott, John J. Haluschak, Walter J. Curran, Hak Choy, Patrick M. Travis, Chandra P. Belani, Phil Bonomi

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(25)

Purpose This phase II noncomparative randomized trial was conducted to determine the optimal sequencing and integration of paclitaxel/carboplatin with standard daily thoracic radiation therapy (TRT), in patients with locally advanced unresected stage

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4fea2864221ba980bc4066ab963fdcc
https://pubmed.ncbi.nlm.nih.gov/16087940

Zobrazit plný text záznamu

O-263 Randomized 3-arm phase II study of paclitaxel (T), carboplatin (C), and thoracic radiation (TRT) for patients with stage III non-small cell lung cancer (NSCLC). Report of locally advanced multimodality protocol (LAMP) - ACR 427

Autor: John J. Haluschak, Patrick M. Travis, Hak Choy, Walter J. Curran, Chandra P. Belani, Phil Bonomi, Charles E. Scott

Publikováno v: Lung Cancer. 41:S77

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0e5e6939821400a14951f126ee709674
https://doi.org/10.1016/s0169-5002(03)91921-0

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání